Trial · NCT00880542
Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery
NCT00880542, Phase 2, Terminated, Jonsson Comprehensive Cancer Center; results first posted 2011-05-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery. Trials, record NCT00880542. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00880542
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery
- NCT number
- NCT00880542
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 7 participants, actual
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Conditions
- Sarcoma
- Interventions
- sorafenib, Ifosfamide
- First posted
- 2009-04-13
- Last updated
- 2020-08-10
- Results first posted
- 2011-05-10
- Limitations and caveats
- This study lost funding and was not able to enroll enough participants to do a complete review.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Using PET/CT Scan to Measure Safety, Toxicity, and Efficacy of Neoadjuvant Sorafenib Tosylate and Ifosfamide in Patients With Resectable High-grade Soft Tissue or Bone Sarcoma. | Participants were followed for duration of study, an average of 1 year. | After cycle 1, a limited PET/CT scan of the affected site will be performed to assess response to sorafenib treatment alone. After cycle 3, prior to surgery, a limited PET/CT scan of the affected site will be performed to assess response to the combination sorafenib and ifosfamide treatment. |
| Secondary | Local and Distant Recurrence-free Survival | conclusion of study |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Using PET/CT Scan to Measure Safety, Toxicity, and Efficacy of Neoadjuvant Sorafenib Tosylate and Ifosfamide in Patients With Resectable High-grade Soft Tissue or Bone Sarcoma. | Participants were followed for duration of study, an average of 1 year. | Due to the study closing early and the few number of participants enrolled, the outcome measures were not done. | ||
| SECONDARY | Local and Distant Recurrence-free Survival | conclusion of study | Due to study closing early and the few number of participants enrolled, the outcome measures were not done. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Treatment Period (Sorafenib+Ifosfamide) | STARTED | Sorafenib + Ifosfamide | 7 | |
| Treatment Period (Sorafenib+Ifosfamide) | COMPLETED | Sorafenib + Ifosfamide | 4 | |
| Treatment Period (Sorafenib+Ifosfamide) | NOT COMPLETED | Sorafenib + Ifosfamide | 3 | |
| Response Evaluation Period(REP): PET/CT | STARTED | Sorafenib + Ifosfamide | 4 | |
| Response Evaluation Period(REP): PET/CT | COMPLETED | Sorafenib + Ifosfamide | 4 | |
| Response Evaluation Period(REP): PET/CT | NOT COMPLETED | Sorafenib + Ifosfamide | 0 | |
| REP: Surgical Resection | STARTED | Sorafenib + Ifosfamide | 4 | |
| REP: Surgical Resection | COMPLETED | Sorafenib + Ifosfamide | 3 | |
| REP: Surgical Resection | NOT COMPLETED | Sorafenib + Ifosfamide | 1 | |
| Post Surgical Evaluation | STARTED | Sorafenib + Ifosfamide | 3 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events84
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Epistaxis | General disorders | Sorafenib + Ifosfamide | 1 | 7 | |
| other | Neutropenia fever | Infections and infestations | Sorafenib + Ifosfamide | 1 | 7 | |
| other | Anemia | Blood and lymphatic system disorders | Sorafenib + Ifosfamide | 3 | 7 | |
| other | Elevated international normalized ratio (INR) | Hepatobiliary disorders | Sorafenib + Ifosfamide | 1 | 7 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Sorafenib + Ifosfamide | 1 | 7 | |
| other | Pancytopenia | Blood and lymphatic system disorders | Sorafenib + Ifosfamide | 1 | 7 | |
| other | Tachycardia | Cardiac disorders | Sorafenib + Ifosfamide | 2 | 7 | |
| other | Chest pain | Cardiac disorders | Sorafenib + Ifosfamide | 1 | 7 | |
| other | chills | General disorders | Sorafenib + Ifosfamide | 1 | 7 | |
| other | Fatigue | General disorders | Sorafenib + Ifosfamide | 2 | 7 |
1 to 10 of 84Source ClinicalTrials.gov
See all 84 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Sorafenib + Ifosfamide | ||
| Total, other adverse events | Sorafenib + Ifosfamide | 7 | 7 |
| Total, serious adverse events | Sorafenib + Ifosfamide | 4 | 7 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA016042 | Cancer Center Support Grant | TEITELL, MICHAEL A | UNIVERSITY OF CALIFORNIA LOS ANGELES | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00880542
GET https://conductscience.org/api/trials/v1/NCT00880542/events?page=2